Journal of the American College of Cardiology
-
J. Am. Coll. Cardiol. · Nov 2007
Clinical TrialNoncontact mapping and radiofrequency catheter ablation of fast and hemodynamically unstable ventricular tachycardia after surgical repair of tetralogy of Fallot.
The goal of this work was to assess efficacy of radiofrequency (RF) ablation of fast ventricular tachycardia (VT) in patients after surgical repair of tetralogy of Fallot (TOF) guided by noncontact mapping. ⋯ In patients with fast and unstable VT after surgical repair of TOF, noncontact mapping helped to identify the tachycardia substrate and allowed for effective and safe treatment by RF ablation.
-
J. Am. Coll. Cardiol. · Nov 2007
Randomized Controlled Trial Comparative StudyIncidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
Our goal was to determine the risk of stroke or non-cerebral embolism associated with paroxysmal compared with sustained atrial fibrillation (AF). ⋯ Patients with paroxysmal AF treated with aspirin plus clopidogrel or OAC have a similar risk for thromboembolic events than patients with sustained AF. This risk can be significantly lowered with OAC. (The ACTIVE W trial; http://www.clinicaltrials.gov/ct/show/NCT00243178;NCT00243178).
-
J. Am. Coll. Cardiol. · Nov 2007
Comparative StudyHeart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values.
Our aim was to determine if a high-performance assay for heart-type fatty acid-binding protein (H-FABP) has a role in predicting all-cause mortality after acute coronary syndrome (ACS). ⋯ Heart-type fatty acid-binding protein predicts long-term mortality after ACS and identifies high-risk patients in a manner that is additive to the GRACE clinical risk factors, troponin, and hs-CRP, possibly as a result of identifying the occurrence of myocardial ischemia with or without necrosis.
-
J. Am. Coll. Cardiol. · Nov 2007
Multicenter Study Comparative StudyComparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
Our aim was assess the prognostic value of midregional pro-atrial natriuretic peptide (MR-proANP) using a new immunoassay in patients with chronic heart failure (HF). ⋯ Midregional proANP is an independent predictor of mortality in patients with chronic HF. Midregional proANP adds prognostic information to NT-proBNP.